Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Rifampin-Resistant Cutibacterium (formerly Propionibacterium) namnetense Superinfection after Staphylococcus aureus Bone Infection Treatment.

Corvec S, Guillouzouic A, Aubin GG, Touchais S, Grossi O, Gouin F, Bémer P.

J Bone Jt Infect. 2018 Nov 24;3(5):255-257. doi: 10.7150/jbji.30029. eCollection 2018.

2.

Draft Genome Sequence of Highly Rifampin-Resistant Propionibacterium namnetense NTS 31307302T Isolated from a Patient with a Bone Infection.

Aubin GG, Kambarev S, Bémer P, Lawson PA, Corvec S.

Genome Announc. 2016 Aug 11;4(4). pii: e00819-16. doi: 10.1128/genomeA.00819-16.

3.

Convergent Evolution Driven by Rifampin Exacerbates the Global Burden of Drug-Resistant Staphylococcus aureus.

Guérillot R, Gonçalves da Silva A, Monk I, Giulieri S, Tomita T, Alison E, Porter J, Pidot S, Gao W, Peleg AY, Seemann T, Stinear TP, Howden BP.

mSphere. 2018 Jan 24;3(1). pii: e00550-17. doi: 10.1128/mSphere.00550-17. eCollection 2018 Jan-Feb.

4.

Rifampin Resistance rpoB Alleles or Multicopy Thioredoxin/Thioredoxin Reductase Suppresses the Lethality of Disruption of the Global Stress Regulator spx in Staphylococcus aureus.

Villanueva M, Jousselin A, Baek KT, Prados J, Andrey DO, Renzoni A, Ingmer H, Frees D, Kelley WL.

J Bacteriol. 2016 Sep 9;198(19):2719-31. doi: 10.1128/JB.00261-16. Print 2016 Oct 1.

5.

Clinical and Biological Features of Cutibacterium (Formerly Propionibacterium) avidum, an Underrecognized Microorganism.

Corvec S.

Clin Microbiol Rev. 2018 May 30;31(3). pii: e00064-17. doi: 10.1128/CMR.00064-17. Print 2018 Jul. Review.

PMID:
29848774
6.

Impact of ciprofloxacin exposure on Staphylococcus aureus genomic alterations linked with emergence of rifampin resistance.

Didier JP, Villet R, Huggler E, Lew DP, Hooper DC, Kelley WL, Vaudaux P.

Antimicrob Agents Chemother. 2011 May;55(5):1946-52. doi: 10.1128/AAC.01407-10. Epub 2011 Feb 28.

8.

RNA polymerase B subunit gene mutations in biofilm-embedded methicillin-resistant Staphylococcus aureus following rifampin treatment.

Tang HJ, Lai CC, Hsueh PR, Chen CC, Wu KY, Lin YC, Zhang CC, Weng TC, Chiu YH, Toh HS, Chiang SR, Yu WL, Ko WC, Chuang YC.

J Microbiol Immunol Infect. 2016 Jun;49(3):394-401. doi: 10.1016/j.jmii.2015.06.006. Epub 2015 Aug 1.

9.

Failure of combination therapy for Staphylococcus aureus bone infection: a case of in vivo selection with resistance to rifampicin and fusidic acid.

Aubin GG, Bémer P, Guillouzouic A, Launay E, Geffroy L, Touchais S, Corvec S.

Infect Dis (Lond). 2016 Sep;48(9):699-702. doi: 10.1080/23744235.2016.1183815. Epub 2016 May 19.

PMID:
27194514
10.

Moxifloxacin plus rifampin as an alternative for levofloxacin plus rifampin in the treatment of a prosthetic joint infection with Staphylococcus aureus.

Wouthuyzen-Bakker M, Tornero E, Morata L, Nannan Panday PV, Jutte PC, Bori G, Kampinga GA, Soriano A.

Int J Antimicrob Agents. 2018 Jan;51(1):38-42. doi: 10.1016/j.ijantimicag.2017.04.011. Epub 2017 Jun 28.

PMID:
28668678
11.

Bactericidal activity of the combination of levofloxacin with rifampin in experimental prosthetic knee infection in rabbits due to methicillin-susceptible Staphylococcus aureus.

Muller-Serieys C, Saleh Mghir A, Massias L, Fantin B.

Antimicrob Agents Chemother. 2009 May;53(5):2145-8. doi: 10.1128/AAC.01163-08. Epub 2009 Mar 9.

12.

Biological cost of rifampin resistance from the perspective of Staphylococcus aureus.

Wichelhaus TA, Böddinghaus B, Besier S, Schäfer V, Brade V, Ludwig A.

Antimicrob Agents Chemother. 2002 Nov;46(11):3381-5.

13.

Delayed methicillin-resistant Staphylococcus aureus-induced osteomyelitis of the tibia after pin tract infection: two case reports.

Hamahashi K, Uchiyama Y, Kobayashi Y, Watanabe M.

J Med Case Rep. 2017 Jan 31;11(1):23. doi: 10.1186/s13256-016-1187-x.

14.

Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus.

Saleh-Mghir A, Muller-Serieys C, Dinh A, Massias L, Crémieux AC.

Antimicrob Agents Chemother. 2011 Oct;55(10):4589-93. doi: 10.1128/AAC.00675-11. Epub 2011 Aug 8.

15.
16.

Immune discrepancies during in vitro granuloma formation in response to Cutibacterium (formerly Propionibacterium) acnes infection.

Aubin GG, Ada Da Silva G, Eishi Y, Jacqueline C, Altare F, Corvec S, Asehnoune K.

Anaerobe. 2017 Dec;48:172-176. doi: 10.1016/j.anaerobe.2017.08.014. Epub 2017 Aug 30.

PMID:
28859990
17.

Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus.

Aubry-Damon H, Soussy CJ, Courvalin P.

Antimicrob Agents Chemother. 1998 Oct;42(10):2590-4.

18.

[Selection of mutant rifampin-resistant Staphylococcus aureus during the therapeutic use of this antibiotic in combinations. 3 cases].

Dellamonica P, Bernard E, Etesse H, Brun Y.

Sem Hop. 1983 Dec 1;59(44):3087-8. French.

PMID:
6320397
19.

In vitro emergence of fluoroquinolone resistance in Cutibacterium (formerly Propionibacterium) acnes and molecular characterization of mutations in the gyrA gene.

Takoudju EM, Guillouzouic A, Kambarev S, Pecorari F, Corvec S.

Anaerobe. 2017 Oct;47:194-200. doi: 10.1016/j.anaerobe.2017.06.005. Epub 2017 Jun 8.

PMID:
28602804
20.

Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.

Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A.

Antimicrob Agents Chemother. 2009 Mar;53(3):1142-8. doi: 10.1128/AAC.00775-08. Epub 2008 Dec 15.

Supplemental Content

Support Center